Patents by Inventor Axel Kahn

Axel Kahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of hepcidin as a regulator of iron homeostasis
    Patent number: 10004784
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • USE OF HEPCIDIN AS A REGULATOR OF IRON HOMEOSTASIS
    Publication number: 20170340710
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 30, 2017
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Use of hepcidin as a regulator of iron homeostasis
    Patent number: 9782453
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: October 10, 2017
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • USE OF HEPCIDIN AS A REGULATOR OF IRON HOMEOSTASIS
    Publication number: 20160166649
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
    Type: Application
    Filed: June 23, 2015
    Publication date: June 16, 2016
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Hepcidin inhibitors for regulating iron homeostasis
    Patent number: 9234903
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anemia.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: January 12, 2016
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Gaël Nicolas, Sophie Vaulont, Axel Kahn
  • Use of hepcidin as a regulator of iron homeostasis
    Publication number: 20070124825
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
    Type: Application
    Filed: November 21, 2006
    Publication date: May 31, 2007
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Use of hepcidin as a regulator of iron homeostasis
    Patent number: 7169758
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 30, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Gaël Nicolas, Sophie Vaulont, Axel Kahn
  • Use of hepcidin as a regulator of iron homeostasis
    Publication number: 20050037971
    Abstract: The invention concerns the use of hepeidin for the diagnosis and therapy of disorders of iron homeostasis. Hepeidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepeidin can he used in the treatment of anaemia.
    Type: Application
    Filed: May 24, 2002
    Publication date: February 17, 2005
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain
    Patent number: 6756523
    Abstract: The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 29, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Axel Kahn, Gildas Le Gal La Salle, Jacques Mallet, Michel Perricaudet, Marc Peschanski, Jean-Jacques Robert
  • Method for treating amyotrophic lateral sclerosis
    Patent number: 6723315
    Abstract: The invention concerns a novel method for treating motor neuron diseases and particularly amyotrophic lateral sclerosis. It consists more particularly in the systemic administration of expression systems of neurotrophic factors.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: April 20, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Jacques Mallet, Philippe Kennel, Frédéric Revah, Axel Kahn, Georg Haase
  • Assays for promoter operability in central nervous system cells
    Patent number: 6458529
    Abstract: The invention concerns a recombinant DNA vector characterized in that it is capable of directing the expression an/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells normally infectable by that adenovirus and (ii) being inserted into said part of genome of an adenovirus under the control of a promoter, either present or also inserted into said genome part and operative in said cells. This recombinant vector finds particular use in the treatment of diseases of the central nervous system, also in gene therapy.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 1, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Axel Kahn, Gildas Le Gal la Salle, Jacques Mallet, Michel Perricaudet, Marc Peschanski, Jean-Jacques Robert
  • Glucose-inducible recombinant viral vector
    Patent number: 6309878
    Abstract: A defective recombinant virus including at least one heterologous gene controlled by a glucose-inducible expression signal, a pharmaceutical composition containing same, and cells transformed using said vector, are disclosed.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: October 30, 2001
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Ruihuan Chen, Bruno Doiron, Axel Kahn